Trial Profile

DAREON-8: A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined With Standard of Care (Platinium, Etoposide, and Anti-PD-L1) in Patients With Extensive-stage Small Cell Lung Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obrixtamig (Primary) ; Atezolizumab; Carboplatin; Cisplatin; Durvalumab; Etoposide
Indications Carcinoma; Small cell lung cancer
Focus Adverse reactions
Acronyms DAREON-8
Sponsors Boehringer Ingelheim

16 Sep 2026 Planned primary completion date changed from 1 Sep 2026 to 31 Mar 2027.
02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
21 May 2026 According to a Boehringer Ingelheim media release, company will present new data from this study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com